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ABSTRACT
Objective To determine if the addition of preventive drug
treatment (β blocker), brief behavioural migraine
management,ortheircombinationimprovestheoutcome
of optimised acute treatment in the management of
frequent migraine.
Design Randomised placebo controlled trial over
16 months from July 2001 to November 2005.
Setting Two outpatient sites in Ohio, USA.
Participants232adults(meanage38years;79%female)
with diagnosisof migrainewith or without auraaccording
to International Headache Society classification of
headache disorders criteria, who recorded at least three
migraines with disability per 30 days (mean 5.5
migraines/30 days), during an optimised run-in of acute
treatment.
Interventions Addition of one of four preventive
treatments to optimised acute treatment: β blocker
(n=53), matched placebo (n=55), behavioural migraine
management plus placebo (n=55), or behavioural
migraine management plus β blocker (n=69).
MainoutcomemeasureTheprimaryoutcomewaschange
in migraines/30 days; secondary outcomes included
change in migraine days/30 days and change in migraine
specific quality of life scores.
Results Mixed model analysis showed statistically
significant (P≤0.05) differences in outcomes among the
four added treatments for both the primary outcome
(migraines/30 days) and the two secondary outcomes
(changeinmigrainedays/30daysandchangeinmigraine
specificqualityoflifescores).Theadditionofcombined β
blocker and behavioural migraine management (−3.3
migraines/30 days, 95% confidence interval −3.2 to
−3.5), but not the addition of β blocker alone (−2.1
migraines/30days, −1.9to −2.2) orbehaviouralmigraine
management alone (−2.2 migraines migraines/30 days,
−2.0 to −2.4), improved outcomes compared with
optimised acute treatment alone (−2.1 migraines/
30 days, −1.9 to −2.2). For a clinically significant (≥50%
reduction) in migraines/30 days, the number needed to
treat for optimised acute treatment plus combined β
blocker and behavioural migraine management was 3.1
compared with optimised acute treatment alone, 2.6
comparedwith optimised acutetreatment plus β blocker,
and 3.1 compared with optimised acute treatment plus
behavioural migraine management. Results were
consistent for the two secondary outcomes, and at both
month 10 (the primary endpoint) and month 16.
Conclusion The addition of combined β blocker plus
behavioural migraine management, but not the addition
of β blocker alone or behavioural migraine management
alone, improved outcomes of optimised acute treatment.
Combined β blocker treatment and behavioural migraine
management may improve outcomes in the treatment of
frequent migraine.
Trial registration Clinical trials NCT00910689.
INTRODUCTION
Migraine is common, affecting approximately 14% of
women and 6% of men worldwide
12; around a third
(31%) of these people report frequent migraines
defined as three or more attacks a month.
23Migraine
causessevereimpairmentorbedrestinmorethanhalf
(57%) of affected people, markedly impairs quality of
life both during and between attacks, increases absen-
teeism and reduces productivity at work, and is asso-
ciated with increased healthcare costs.
13-7 Frequent
migraine is also a risk factor for progression from epi-
sodic migraine to chronic migraine (at least 15 head-
ache days a month
8), which commonly presents as
debilitating daily or near daily headaches.
9-11 Recent
findings suggest that frequent migraines are associated
with structural changes in the brain.
12-14 The personal,
family, and societal impact of frequent migraines, plus
the high risk of disease progression and possible neu-
rodegenerative changes in the brain, have led to calls
formoreaggressivemanagementoffrequentmigraine
in primary care.
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primary care, management seems to be
problematic.
3716-19 This may reflect the fact that the
management of frequent migraine can be challenging
inprimarycare,needingdrugsforacutetreatmentand
for prevention, as well as changes in patients’
behaviour.
320-24
The average reduction in migraines of 40-50% seen
intrialsofpreventivedrugtreatmentisclinicallymean-
ingful but only moderate in magnitude.
2125-27 Limita-
tions of the evidence base for preventive drugs
include the predominance of short term (six months
or less) trials, dropout rates that approach 50% of ran-
domised participantsat the primaryend point,
28-30 and
the lack of trials comparing different preventive treat-
ments.Behaviouralmigrainemanagementusesrelaxa-
tion, thermal biofeedback, stress management, and
other behavioural interventions to teach skills for reg-
ulating physiological, mental, and behavioural
responses to prevent, abort, and cope with
migraines.
31-33 The average reduction in migraines of
40-50%seen intrialsof behavioural migrainemanage-
ment closely parallels results obtained in trials of pre-
ventive drugs.
3234-36 Limitations of the evidence base
for behavioural treatments include the predominance
ofsmalltrials,thefewplacebocontrolledtrials,andthe
lack of trials that compare behavioural interventions
with preventive drugs.
3435
The possibility that the combination of preventive
drug treatment and behavioural migraine manage-
ment can improve on the outcomes achieved with
eithertreatmentmodalityaloneisofparticularinterest
but has yet to be formally evaluated.
3437 Additional
information about the comparative benefits of preven-
tive treatment and behavioural migraine management
when added to contemporary acute treatment is also
needed.
The 5-HT1B/D agonists or “triptans” have markedly
improved the effectiveness of the acute treatment of
migraine.
3839 However, the very effectiveness of con-
temporary acute treatment creates uncertainty about
the benefits of preventive treatment beyond “opti-
mised” acute treatment alone.
4041 Contemporary
acute treatment effectively controls even frequent
migraines in some people.
4041 Administered early in
the migraine episode, acute treatment can terminate a
migraine,
42-46 preventing some of the associated psy-
chosocial and biological consequences of a full blown
migraine episode (Bernstein R, personal communica-
tion, 2008).
164748 On the other hand, the additional
benefits of a preventive treatment may be smaller
when acute treatment is optimised as recommended
inclinicalpracticethanwhenacutetreatmentisuncon-
trolledorsuboptimal,whichisthesituationinthetypi-
caltrialofpreventivetreatment.
4041Informationabout
the benefits of preventive treatment when acute treat-
ment is optimised as recommended in clinical practice
is lacking in trials of preventive drugs.
The Treatment of Severe Migraine trial aimed to
determine if the addition of preventive drug treatment,
behaviouralmigrainemanagement,orthecombination
of the two improves the outcomes of optimised acute
treatment. Participants with frequent migraines asso-
ciated with disability received optimised acute treat-
ment, and if their migraines remained uncontrolled
they were randomised toone offour added treatments:
preventive (β blocker) treatment, placebo, behavioural
migraine management plus placebo, or behavioural
migraine management plus preventive treatment. We
obtained electronic headache diary recordings for the
full16monthsofthetrial,includinga12monthevalua-
tion phase, and we assessed migraine related impair-
ments in quality of life at multiple points over the
16 months of the trial.
METHODS
Participants
We recruited participants from physicians’ referrals
and local advertisements at two outpatient sites: one
site with two offices serving greater Columbus, Ohio,
and one site in Athens, Ohio, serving rural southeast-
ern Ohio. Inclusion criteria were age 18 to 65 years,
diagnosis of migraine (with or without aura) according
totheinternationalclassificationofheadachedisorders
criteria at two separate evaluations during the evalua-
tion clinic visit,
49 and diary confirmed criteria for
severity of migraine during the optimised acute treat-
ment run-in of at least three migraines with disability
per30days.
2Exclusioncriteriawerediagnosisofprob-
able medication overuse headache according to the
international classification of headache disorders cri-
teria, a pain disorder other than migraine as the pri-
mary presenting problem, 20 or more days with
headache a month, contraindication or sensitivity to
any study drug, current use of migraine preventive
drugs (with participant’s preference or welfare contra-
indicating withdrawal), current psychological treat-
ment, psychiatric disorder needing immediate or
priority treatment, and inability to read and under-
stand the study materials; for women, current or
planned breast feeding or pregnancy or unwillingness
to use an established contraceptive method were also
exclusion criteria. All participants gave written
informed consent.
Study design and treatments
During the five week run-in of optimised acute treat-
ment, all participants who met the inclusion criteria at
the evaluation in the clinic received optimised acute
treatmentasdescribedbelow.Participantswhocontin-
ued to meet the criteria for severity of migraine on the
basisoftheirhandheldelectronicdiaryrecordingsdur-
ing the run-in period were then randomised, with stra-
tification by sex and by site, to one of the four added
treatments: β blocker, matched placebo, behavioural
migrainemanagementplusβblocker,andbehavioural
migraine management plus placebo. A statistician not
otherwise connected with the study generated the ran-
domisation sequence by computer and supplied it in
sealed opaque envelopes. After confirming that the
electronic headache diary recordings from the run-in
period qualified the participant, the site manager
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cipant by opening the next envelope in the sequence.
Participants who did not qualify were offered or
referred for continuing treatment.
Each of the four treatment protocols required four
monthly visits to the clinic and three telephone con-
tacts during the three month treatment/dose adjust-
ment phase (months 1-4) in which the dose of β
blocker or placebo was adjusted and behavioural
migraine management was administered. Telephone
contacts were scheduled at the midpoint between the
monthly clinic visits in weeks 3, 7, and 10. During the
12 month (months 5-16) evaluation phase, clinic visits
were scheduled at months 5, 7, 10, 13, and 16. The β
blockerandplacebotreatmentswereadministeredina
standard double blind fashion. Treatment conditions
were blinded only for the preventive drug component
andnotfortheadministrationofbehaviouralmigraine
management. The 16 month trial took place between
July 2001 and November 2005.
Optimised acute treatment
The acute treatment protocol emphasised treatment
with a 5-HT1B/D agonist or triptan. Non-steroidal anti-
inflammatory (ibuprofen) and anti-emetic (metoclopra-
mide) agents could be added as needed.
204350 The
choice of triptans available at the time of the study
design (rizatriptan, sumatriptan), the route(s) of admin-
istrationoftriptan(oral,nasalspray,subcutaneousinjec-
tion), and the addition of a non-steroidal anti-
inflammatory or anti-emetic agent were tailored to the
participant’s preference, treatment history, and
response to acute treatment.
5152 Rescue drugs (such as
steroids) could also be prescribed. We used individua-
lised handouts and a phone call at week 3 of the run-in
period to help participants to evaluate and optimise
their acute treatment (for example, to adjust the dose
tominimisesideeffects).Trialsofpreventivedrugsgen-
erally have not specified a protocol for acute treatment
or attempted to optimise acute treatment but permitted
the use of acute treatments as rescue drugs. In these
trials, participants recorded use of rescue drugs, but
these data have not been reported in publications.
28-30
β blocker and placebo
In this double blind protocol, we attempted to maxi-
misetheefficacyandtolerabilityofβblockertreatment
by using a flexible target dose, by treating participants
who were unable to tolerate propranolol hydrochlor-
ide with nadolol, and by including a proven inter-
vention to maximise adherence.
5354 Treatment was
started with one capsule (60 mg long acting proprano-
lol hydrochloride or matched placebo) and increased
tothreecapsules(180mgormatchedplacebo)atweek
12 as tolerated. Participants who did not tolerate at
least two capsules (120 mg) of long acting propranolol
hydrochloride or matched placebo, and in the judg-
ment of the treating neurologist (FJO, GEC) were
unimproved,wereswitchedwithblindnessmaintained
to the second drug—nadolol for participants who had
beenreceiving propranolol hydrochloride ormatched
nadolol placebo for participants who had been receiv-
ingpropranololplacebo.Participantsinitiallyreceived
a single 40 mg capsule of nadolol or matched placebo.
Thedosewasincreasedatthenextvisittotwocapsules
(80 mg) as tolerated. At week 12, the dose was stabi-
lised at the highest tolerated level. In the evaluation
phase, we permitted an increase to four capsules of
long acting propranolol hydrochloride (240 mg) or
matched placebo or three capsules of nadolol
(120 mg) or matched placebo. We used instructional
handouts and the three monthly phone contacts to
identifyandrectifyproblemswithadherence(thiscon-
stituted the adherence intervention).
5354
Behavioural migraine management
Behavioural migraine management is structured,
manually guided treatment that maximises clinical
relevance by teaching multiple migraine management
skills and tailoring treatment to the participant’s pro-
gress, preferences, and migraine characteristics.
55
Migraine management skills are introduced at each of
four clinic visits at which the performance of each
migraine management skill can be observed and cor-
rected. However, the learning and application of
migraine management skills occurs primarily between
clinic visits, guided by the behavioural migraine man-
agement workbook and accompanying 10 audio
lessons.
56
The first behavioural migraine management session
provides an overview of the pathophysiology of
migraine, highlighting the relevance of behavioural
migraine management skills, and introduces relaxation
(muscle stretching, deep breathing, progressive muscle
relaxation, relaxation imagery), emphasising the cor-
rect performance of progressive muscle (12 muscle
groups) relaxation.
57 Month 1 homework assignments
focusonmasteringprogressivelymorerapidrelaxation
techniquesandintroduceexercisesforidentifying“pro-
dromal” migraine warning signs and migraine triggers.
Building on previous homework, session 2 focuses on
the development of a strategy for managing migraine
triggers and on using early warning signs as a cue to
use relaxation, trigger management, and, where indi-
cated, acute drugs effectively in managing migraines.
Month 2 homework assignments focus on the integra-
tionofquick(relaxationbyrecall,cuecontrolledrelaxa-
tion)techniquesintothe participant’sdailyroutine,
57 as
wellasonapplyingandrefiningtheparticipant’strigger
management strategy and plan for responding to early
migraine warning signs. Three options are available in
session 3: continue with previously introduced “basic”
migraine management skills, introduce cognitive-beha-
vioural stress management if stress is a salient migraine
trigger,
5558 or introduce thermal biofeedback (“hand-
warming”)trainingwithaportabledigitalhomethermal
biofeedback device (Model SC-911, Bio-Medical
Instruments, Warren, MI) if stress is not a notable
migraine trigger.
55 In each case, the relevant beha-
vioural migraine management skills are introduced
and performed by participants in session 3, allowing
for corrective feedback, and the behavioural migraine
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 3 of 12management manual and audiotapes guide further
learning, application, and refinement of the migraine
managementskillsinmonth3.Atthefinalclinicsession,
problems encountered in using behavioural migraine
management skills are resolved and a written migraine
management plan is prepared on the basis of partici-
pants’ preferences and observations of the usefulness
of the various migraine management activities
attempted during treatment. Lastly, relapse prevention
orwaysofcopingwithproblemsthatcommonlyarisein
effectively using behavioural migraine management
skills over the long term are tackled. For participants
receiving behavioural migraine management, we used
the three monthly phone contacts to identify and solve
problems encountered in using behavioural migraine
management skills as well as to identify and correct
anydrugadherenceproblems.Amoredetaileddescrip-
tionoftreatmentprocedureshasbeengivenbyLipchik
and colleagues.
55
Three masters level and two doctoral level health
psychologists administered behavioural migraine
management in four sessions of one hour each at the
four monthly clinic visits also used for adjustments of
doses of drugs. Behavioural migraine management
therapists had training that included study of and
examination on elements of the treatment protocol,
role playing of each therapy session until competence
had been demonstrated, and treatment of training
cases that were tape recorded for supervision until
competence was demonstrated. All trial sessions were
tape recorded and reviewed on an ongoing basis for
adherence to the protocol.
Outcome measures
Participants recorded headaches, associated symp-
toms, and other characteristics of their headaches, as
well as drug use, in a handheld electronic (Palm OS )
diary for the 16 months of the trial.
5960 The number of
migrainesper30 days (with at leasta 24 hourpain-free
period between distinct migraines) and the number of
migraine days (defined as a day, from 0001 to 2400, in
whichamigrainewasrecorded)per30dayscamefrom
the electronic diary. We assessed the impact of
migraines on quality of life with the migraine specific
quality of life version 2.1, a 14 item self reported mea-
surewithestablishedpsychometricproperties.
6162The
migraine specific quality of life was administered by
computer before the run-in of optimised acute treat-
ment, at clinic visits 1 and 3 during the treatment/
dose adjustment phase, as well as at each of the five
clinic visits during the evaluation phase. The time-
frame for the migraine specific quality of life was one
month,sothemigrainespecificqualityoflifescoreand
the(monthly)migrainediarydatawereassessedforthe
same time period. Thetotal score for migraine specific
quality of life ranges from 14 to 84, with higher scores
reflecting greater impairment in quality of life.
Hypotheses and statistical methods
Wedesignedthisstudytodetermineiftheadditionofβ
blocker, behavioural migraine management, or
combined β blocker plus behavioural migraine man-
agement improved outcomes with optimised acute
treatment alone and, secondarily, whether the three
added treatments differed in effectiveness.
The primary outcome was change in number of
migraines per 30 days at month 10 relative to the run-
in period. Secondary outcomes included change in
number of days with migraine per 30 days and change
in migraine related impairments in quality of life
(migraine specific quality of life scores) at month 10
relative to the run-in period; longer term changes in
all three outcome variables at month 16 were second-
ary outcomes. Finally, we calculated the proportion of
participants who showed a clinically significant
improvement in migraines, defined as at least a 50%
reduction in migraines per 30 days at month 10 as a
secondary outcome.
63
We used χ
2tests to compareattrition and side effects
acrosstherelevanttreatmentgroups.Efficacyanalyses
wereintentiontotreatanalysesthatincludedallrando-
mised participants (n=232). We used a mixed model
with fixed effects for treatment (four treatment condi-
tions), time (defined as the natural log of months), and
the treatment by time interaction to obtain maximum
likelihood estimates of missing values and to evaluate
treatment effects (PROC MIXED, SAS 9).
64-66 A
mixed model for repeated measures not only can
yield unbiased estimates of parameters when missing
observationsareexplainedbyobservedoutcomes,but
not by unobserved outcomes (missing at random), but
alsoperformssurprisinglywellevenonsimulatedclin-
ical trial data that include both observations missing at
random and observations missing not at random.
67-70
We fitted the above model by using the restricted
maximum likelihood estimation to obtain the best fit-
ting variance-covariance matrix. We used the best fit-
ting, by the Akaike’s information criterion,
heterogeneous toeplace covariance structure to
account for within participant correlation over time
for all outcome analyses. As noted above, we used a
mixedmodelwithfullmaximumlikelihoodestimation
to obtain estimates for the fixed effects for all outcome
analyses. We modelled all three outcome variables as
continuous variableswith normal errors. For migraine
specificqualityoflifescoresonly,ascoreforbeforethe
run-in of optimised acute treatment was available; we
thus included this pre-treatment score as a covariate in
the above model for this analysis.
When the omnibus treatment by time interaction
was statistically significant (P<0.05, two tailed), we
did six pairwise comparisons with Bonferroni correc-
tion (P<0.0083) at month 10, the primary end point,
and, to evaluate longer term treatment effects, at
month 16. The first three comparisons considered the
primarystudyquestionbycomparingeachofthethree
additive treatments with optimised acute treatment
plusplacebo.Threeadditionalcomparisonscompared
the three added treatments with one another. At the
primary end point at month 10, we also compared
the proportion of participants who showed clinically
significant improvements, defined as at least a 50%
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run-in of optimised acute treatment,
63 across the four
treatment groups by using χ
2, with missing values
imputedasdescribedabove.Ifthisomnibusχ
2wassig-
nificant(P<0.05,two tailed),we usedχ
2 testswithBon-
ferroni correction (P<0.0083) to test the above six
comparisons.
Two sensitivity analyses repeated the above mixed
model analyses with only participants (n=214) who
provided at least one post-randomisation data point
and with only participants (n=182) who completed
the treatment/dose adjustment phase and were
assessed at month 5. The post-tests power to detect a
between group difference in improvement of 1 (SD
1.5) migraine per 30 days, an adjusted α of 0.0083,
and our initially planned number of participants of
240 was 0.83.
RESULTS
Participants’ characteristics
Table 1showsthedemographicandclinicalcharacter-
istics of the 232 participants. Participants were predo-
minantly (79%) female and, on average, recorded 5.5
migrainesand8.5dayswithmigraineper30days.The
previousproviderofheadachecarewasaprimarycare
physician or gynaecologist for 156 (68%) of the 229
participants who provided this information and a neu-
rologist for 29 (13%); 40 (17%) were lapsed consulters,
defined as not having consulted a physician in the
previous six months despite persistent headache
problems.
71
Attrition
Figure 1 shows the flow of participants through the
trial. Of 1382 potential participants, 997 were elimi-
nated at the initial phone screening: 555 did not meet
the criteria for diagnosis or severity of migraine, 174
reported an exclusionary medical condition or contra-
indication or intolerance to a study drug, 71 were tak-
ing or did not wish to take preventive treatment for
migraine, 111 were not interested in participation,
and 86 could not be scheduled for evaluation in the
clinic (lost to follow-up or lived at too great a distance
for clinic visits). At the subsequent evaluation, 76
potential participants were excluded: 33 chose not to
participate, and 43 were judged ineligible. Of the 43
participants judged ineligible, nine did not have a pri-
mary diagnosis of migraine, four had a diagnosis of
probable medication overuse headache, 24 had a con-
traindication or previous intolerance to a study drug,
five had a psychiatric disorder that needed priority
treatment, and one had another pain disorder as the
primary presenting problem. Finally, 77 potential par-
ticipants were eliminated at the end of the run-in of
optimised acute treatment on the basis of their diary
recordings:44recorded20ormoreheadachedaysper
30 days, and 33 didnot meet the criteria for severity of
migraine.
Table 1 |Demographic and clinical characteristics. Values are numbers (percentages) unless stated otherwise
Characteristics
Optimised acute treatment
Optimised acute treatment plus behavioural
migraine management
Total (n=232) Plus placebo (n=55) Plus β blocker (n=53) Plus placebo (n=55) Plus β blocker (n=69)
Demographics
Mean (SD) age at entry (years) 39.5 (10.2) 37.7 (10.1) 37.1 (9.4) 38.3 (10.9) 38.2 (10.2)
Female sex 45 (82) 45 (85) 45 (82) 49 (71) 184 (79)
Racial or ethnic group*:
White 47 (85) 44 (83) 48 (87) 55 (80) 194 (84)
Black 7 (13) 9 (17) 7 (13) 8 (12) 31 (13)
Hispanic 1 (0.2) 0 0 2 (3) 3 (1)
A s i a n 0 0 0 2( 3 ) 2( 1 )
Pacific Islander 0 0 0 1 (1) 1 (0)
American Indian 0 0 0 1 (1) 1 (0)
Income level†:( n =53) (n=44) (n=50) (n=63) (n=210)
≤$40 000 18 (34) 17 (39) 19 (38) 21 (33) 75 (36)
$40 001-80 000 22 (42) 22 (50) 13 (26) 25 (40) 82 (39)
>$80 000 13 (25) 5 (11) 18 (36) 17 (27) 53 (25)
Migraine characteristics
Mean (SD) migraines/30 days 5.5 (1.9) 5.2 (1.9) 5.6 (2.0) 5.7 (1.9) 5.5 (1.9)
Mean (SD) migraine days/ 30 days 8.4 (3.5) 8.6 (3.3) 8.1 (3.4) 8.7 (4.0) 8.5 (3.6)
Mean (SD) migraine specific quality of life score 40.3 (13.4) 40.3 (13.4) 38.5 (12.4) 39.4 (11.9) 39.6 (12.7)
Migraine with aura 16 (6.9) 10 (4.3) 9 (3.9) 17 (7.3) 52 (22)
Mean (SD) disease duration (years):
At current frequency 6.6 (8.6) 3.9 (4.6) 5.6 (6.9) 6.5 (8.2) 5.7 (7.3)
Problem headaches 15.6 (10.8) 13.3 (9.5) 16 (8.7) 15.1 (10.0) 15.0 (9.8)
*Self identified.
†22 participants declined to report family income.
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mised participants was 24% (56 participants) at
month 5, 35% (81 participants) at month 10, and 49%
(114 participants) over the full 16 months of the trial.
Attrition did not differ between the four treatment
groups at the month 5, 10, or 16 month evaluations
(all P>0.70).
Dosing and protocol adherence
Acute treatment
One hundredand twelve(48%) ofthe 232 randomised
participants were using a triptan for acute treatment
before the run-in of optimised acute treatment. How-
ever, study neurologists judged previous acute treat-
ment to be suboptimal for all 232 participants.
Screened by phone (n=1382)
Evaluated (n=385)
Began run-in of optimised acute treatment (n=309)
Optimised acute treatment
+ behavioural migraine
management + β blocker (n=69)
Optimised acute treatment +
behavioural migraine
management + placebo (n=55)
Optimised acute treatment +
β blocker (n=53)
Optimised acute treatment
+ placebo (n=55)
Did not provide post
run-in data (n=1)
Did not provide post
run-in data (n=2)
Did not provide post
run-in data (n=10)
Did not provide post
run-in data (n=5)
Began treatment (n=59) Began treatment (n=50) Began treatment (n=52) Began treatment (n=53)
Evaluated at 5 months (n=48) Evaluated at 5 months (n=42) Evaluated at 5 months (n=42) Evaluated at 5 months (n=44)
Excluded (n=997):
  Ineligible (n=800)
  Not interested (n=111)
  Lost after screening (n=86)
Excluded (n=76):
  Ineligible (n=43)
  Not interested (n=33)
Dropped out (n=9):
  Moved or lost to follow-up (n=3)
  Time demands* (n=1)
  Side effects (T)† (n=2)
  Lack of efficacy (n=2)
  Protocol violation‡ (n=1)
Dropped out (n=10):
  Moved or lost to follow-up (n=4)
  Side effects (B)† (n=3)
  Lack of efficacy (n=1)
  Pregnancy§ (n=2)
Dropped out (n=8):
  Moved or lost to follow-up (n=1)
  Time demands* (n=4)
  Side effects (B)† (n=2)
  Perceived improvement (n=1)
Dropped out (n=11 ):
  Moved or lost to follow-up (n=3)
  Time demands* (n=8)
Dropped out (n=4):
  Moved or lost to follow-up (n=2)
  Side effects (B)† (n=1)
  Protocol violation‡ (n=1)
Dropped out (n=7):
  Moved or lost to follow-up (n=5)
  Lack of efficacy (n=1)
  Protocol violation‡ (n=1)
Dropped out (n=7):
  Moved or lost to follow-up (n=1)
  Time demands* (n=4)
  Side effects (B)† (n=2)
  Lack of efficacy (n=1)
  Pregnancy§ (n=2)
Dropped out (n=10):
  Moved or lost to follow-up (n=3)
  Time demands* (n=2)
  Side effects (B)† (n=2)
  Lack of efficacy (n=2)
  Pregnancy§ (n=1)
Dropped out (n=7):
  Moved or lost to follow-up (n=1)
  Time demands* (n=1)
  Side effects (B)† (n=4)
  Lack of efficacy (n=1)
Evaluated at 10 months (n=41) Evaluated at 10 months (n=35) Evaluated at 10 months (n=35) Evaluated at 10 months (n=40)
Evaluated at 16 months (n=35) Evaluated at 16 months (n=28) Evaluated at 16 months (n=25) Evaluated at 16 months (n=30)
Dropped out (n=10):
  Time demands* (n=1)
  Side effects (B)† (n=4)
  Lack of efficacy (n=3)
  Unrelated medical condition
    (n=2)
Dropped out (n=7):
  Moved or lost to follow-up (n=1)
  Time demands* (n=1)
  Side effects (T)† (n=1)
  Lack of efficacy (n=3)
  Unrelated medical condition
    (n=1)
Dropped out (n=6):
  Moved or lost to follow-up (n=2)
  Side effects (B)† (n=2)
  Perceived improvement (n=1)
  Pregnancy§ (n=1)
Randomised (n=232)
Excluded (n=77):
  Ineligible (n=77)
Fig 1 | Flow of participants in trial. *Reported that other time demands prevented completion of trial tasks (such as completing
study appointments). †Side effects attributed to triptan (T) or β blocker (B). ‡Discontinued from trial for protocol violation (for
example, failed to take preventive drug). §Decided to become or became pregnant
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thefourtreatmentgroups,eitherduringtherun-inper-
iod or at any point in the trial (P>0.05). All 232 subse-
quentlyrandomisedparticipantshadbeentreatedwith
a triptan during the run-in of optimised acute treat-
ment,using a mean of1.2 (SD 0.9) dosesper migraine.
In month 5, 157/168 (93%) participants both had a
migraine and treated it with a triptan, using a mean of
1.8 (SD 1.1) dosesper migraine;in month 10, 124/133
(93%) participants both had a migraine and treated it
with a triptan, using a mean of 1.8 (1.1) doses per
migraine; finally, in month 16, 89/96 (93%) partici-
pants both had a migraine and treated it with a triptan,
using a mean of 1.9 (1.1) doses per migraine.
Preventive treatment
At month 5, after dose adjustment, 72/90 (80%) parti-
cipants in the active drug groups were taking long act-
ing propranolol hydrochloride (7 at 60 mg, 18 at
120 mg, 47 at 180 mg) and 18 were taking nadolol
(10 at 40 mg, 8 at 80 mg). At month 10, 61/76 (80%)
participants were taking long acting propranolol
hydrochloride (6 at 60 mg, 16 at 120 mg, 39 at
120 mg, 1 at 180 mg) and 15 were taking nadolol (7 at
40 mg, 6 at 80 mg, 2 at 120 mg). At month 16, 52/60
(87%)participantsweretakinglongactingpropranolol
hydrochloride(5at60mg,14at120mg,33at120mg)
andeightweretakingnadolol(5at40mg,2at80mg,1
at 120 mg).
Daily electronic diary recordings indicated high
adherence; about 90% of participants recorded that
they took their preventive drug on at least 25/
30 days. Specifically, for β blocker, 85/90 (94%) parti-
cipants at month 5, 72/76 (95%) participants at month
10, and 54/59 (92%) participants with available data at
month 16 recorded taking their preventive drug on at
least 25/30 days. Resting heart rate was reduced from
baseline levels in the β blocker groups at each assess-
ment (−10.6 (95% confidence interval −13.2 to −7.9)
beats/min (n=89) at month 5; −9.4 (−12.1 to −6.7)
beats/min (n=76) at month 10; −6.8 (−9.9 to −3.6)
beats/min (n=59) at month 16), but essentially
unchanged in the placebo groups (−1.1 (−3.7 to 1.5)
beats/min (n=85) at month 5; −0.5 (−2.9 to 1.9) beats/
min (n=74) at month 10; −1.7 (−5.1 to 1.5) beats/min
(n=57) at month 16).
Adherence to behavioural migraine management
was also reasonably high; approximately 70% of parti-
cipants showed high adherence to behavioural
migraine management homework assignments
(defined as completion of at least 60% of behavioural
migraine management homework assignments with
good or excellent ratings for quality of homework by
the counsellor). Specifically, for the 90 participants
receiving behavioural migraine management evalu-
ated at month 5, adherence data for session 2 were
available for 87, and 62 (71%) of these participants
showed high adherence to homework assigned at ses-
sion 2; similarly 68/89 (76%) participants with avail-
able adherence data for session 3 showed high
adherencetosession3homeworkassignments;finally,
68/88(77%)participantswithavailableadherencedata
forsession4showedhighadherencetosession4home-
work.
Outcomes
Mixed model analysis yielded significant effects for
both time (P<0.001) and the treatment by time inter-
action (at least P<0.05) for each of the three outcome
measures,indicatingstatisticallysignificantdifferences
in outcomes with the four treatments over time. At the
primary end point of month 10, figures 2 and 3 and
table 2 show that each of the four treatments yielded
clinically meaningful improvements in number of
migraines and days with migraine. However, only the
addition of combined β blocker and behavioural
migraine management improved on the outcomes
obtained withoptimised acute treatmentalone. Differ-
ences among the three remaining treatments were
neither clinically meaningful in magnitude nor statisti-
cally significant. The longer term pattern of results at
month 16 was identical.
Theproportionofparticipantsclassifiedasclinically
improved (≥50% reduction in migraines) at the pri-
mary end point (month 10) differed similarly across
groups (P<0.001). Optimised acute treatment plus β
blocker and behavioural migraine management, with
53/69 (77%) participants clinically improved, differed
from the remaining three treatments (P≤0.001),
whereas differences among the other three treatments
were neither clinically meaningful nor statistically sig-
nificant: 22/55 (40%) optimised acute treatment alone
participants, 18/53 (34%) optimised acute treatment
plusβblockerparticipants,and19/55(36%)optimised
acute treatment plus behavioural migraine manage-
ment participants were classified as clinically
improved. For optimised acute treatment plus β
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primary end point and longer term assessment point
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number needed to treat was 3.1 compared with opti-
mised acute treatment alone, 2.6 compared with opti-
mised acute treatment plus β blocker, and 3.1
compared with optimised acute treatment plus beha-
vioural migraine management.
Migraine specific quality of life scores were higher at
the beginning (mean 39.6, SD 12.7) than at the end of
the run-inofoptimised acute treatment (mean 34.0,SD
10.3)(P<0.01).Figure4andtable 2showthatadditional
improvements in migraine specific quality oflifescores
occurred with all four treatments at the primary end
point; optimised acute treatment plus β blocker and
behavioural migraine management yielded improve-
ments that were larger than the remaining three treat-
ments at both the month 10 and month 16 evaluations.
Optimised acute treatment plus behavioural migraine
managementalsoyielded larger reductionsinmigraine
specific quality of life scores than did optimised acute
treatment alone or optimised acute treatment plus β
blockeratmonth10,butdifferencesbetweenoptimised
acute treatment alone and optimised acute treatment
plus β blocker were not statistically significant at
month 16.
The two sensitivity analyses also yielded significant
treatment by time interactions (P≤0.05) for each of the
three outcome variables. For migraines and for
migraine days, the same treatment group differences
were statistically significant in the two sensitivity ana-
lyses and in the intention to treat analyses at both
month 10 and month 16. For migraine specific quality
of life scores, the two sensitivity analyses and the inten-
tion to treat analysis differed for two planned compari-
sons. In the sensitivity analysis (n=182) that included
only participants who completed the treatment/dose
adjustment phase, differences between optimised acute
treatment plus behavioural migraine management and
both optimised acute treatment alone and optimised
acute treatment plus β blocker were statistically signifi-
cantatbothmonth10andmonth16,ratherthanonlyat
month 10 as was seen in the intention to treat analysis.
Adverse effects
Of the 208 participants who completed the first dose
adjustmentsession,atleastonesideeffectwasreported
duringthedoseadjustmentphaseby54/110(49%)par-
ticipantsreceivingβblockerand40/98(41%)receiving
placebo (P=0.23). After dose adjustment at month 5,
side effects were reported by only 18/90 (20%) partici-
pants taking β blocker and 9/86 (10%) taking placebo
(P=0.08).Theonesideeffectreportedby5%ormoreof
participants was fatigue, reported by 9/90 (10%) parti-
cipants taking β blocker and 5/86 (6%) taking placebo
(P=0.31). For the 214 participants who provided post-
baseline data (fig 1), attrition attributed to the side
effects of β blocker treatment was 7/110 (6%) partici-
pants assigned to β blocker compared with 5/93 (5%)
assigned to placebo (P=0.77) at month 5. Over the full
16monthsofthetrial,attritionattributedtosideeffects
of β blocker treatment was 13/101 (13%) participants
assigned to β blocker compared with 7/93 (8%)
assigned to placebo (P=0.25).
DISCUSSION
To our knowledge, this is the first controlled trial to
examine the separate and combined effects of
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Table 2 |Mean change (95% confidence interval) and results of pairwise comparisons for four treatments at month 10 and month 16
Outcome measure
Optimised acute treatment
Optimised acute treatment plus behavioural
migraine management
Plus placebo (n=55) Plus β blocker (n=53) Plus placebo (n=55) Plus β blocker (n=69)
Month 10
Migraines/30 days −2.1 (−1.9 to −2.2) −2.1 (−1.9 to −2.2) −2.2 (−2.0 to −2.4) −3.3* (−3.2 to −3.5)
Migraine days/30 days −3.3 (−3.0 to −3.6) −3.9 (−3.5 to −4.2) −3.3 (−2.9 to −3.7) −5.4* (−5.2 to −5.6)
Migraine specific quality of life scores −7.1 (−6.3 to −7.8) −7.1 (−6.6 to −7.7) −8.6* (−8.2 to −8.9) −13.0* (−12.5 to −13.5)
Month 16
Migraines/30 days −2.5 (−2.3 to −2.6) −2.5 (−2.2 to −2.8) −2.7 (−2.5 to −2.9) −3.8* (−3.5 to −4.0)
Migraine days/30 days −3.9 (−3.5 to −4.3) −4.5 (−4.0 to −5.1) −4.1 (−3.8 to −4.5) −6.1* (−5.6 to −6.6)
Migraine specific quality of life scores −8.8 (−8.1 to −9.5) −8.5 (−7.6 to −9.4) −9.6 (−9.0 to −10.3) −15.2* (−14.4 to −16.0)
*Differ significantly from other three treatments with Bonferroni adjustment (P<0.0083).
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management, as well as the first trial to determine if
these treatments improve the outcomes obtained with
an “optimised” acute treatment regimen. Only the
combination of β blocker treatment and behavioural
migraine management improved outcomes with opti-
mised acute treatment. This combined treatment
yielded larger improvements in number of migraines,
number of days with migraine, and quality of life at
both short term (month 10) and longer term (month
16) assessments than did the other three treatments.
Preventive (β blocker) treatment combined with brief
behavioural migraine management thus may be a pro-
misingmethodofimprovingoutcomesin the manage-
ment of frequent impairing episodic migraine.
In contrast to results obtained with combined treat-
ment,neitherβblockeralonenorbehaviouralmigraine
management alone improved on the outcomes of opti-
mised acute treatment. However, neither β blocker
alone nor behavioural migraine management alone
were ineffective. The approximately 50% reductions
in migraine episodes and in migraine days seen with β
blocker andwith behavioural migrainemanagement in
this trial compare favourably with the average reduc-
tions in migraines seen in previous trials of β blocker
and of behavioural therapy.
2125-273234-36 However, opti-
mised acute treatment alone yielded improvements in
migrainesandqualityoflifeofthesamemagnitude.Asa
result,wewereunabletoshowthattheadditionofeither
β blocker alone or behavioural migraine management
alone improved on the substantial improvements
achieved with optimised acute treatment.
Optimised acute treatment
The effectiveness of optimised acute treatment in this
study is consistent with the observation that the very
effectiveness of contemporary acute treatment can
limitthebenefitsobtainedwiththe additionofpreven-
tivetreatment.
4041However,thistrialwasnotdesigned
to evaluate the effectiveness of the optimised acute
treatment protocol and thus did not include a compar-
ison group that did not receive either optimised acute
treatmentorpreventivetreatment.Concernsaboutthe
possibledeleteriouspsychosocialandbiologicaleffects
of frequent disabling migraines prevented inclusion of
this control group.
61112147273 As a result, we cannot
exclude the possibility that improvements seen with
optimised acute treatment reflect attention and non-
specific effects associated with participation in a clini-
caltrial,apreventivedrugplaceboeffect,regressionto
the mean, or the natural course of the disorder.
74 Parti-
cipants’ longstanding history of frequent migraines
and the randomisation of only the participants who
had frequent migraines with disability despite receiv-
ingoptimisedacutetreatmentduringtherun-inperiod
argue against, but do not eliminate, this possibility.
Nevertheless, our results raise the possibility that the
results of clinical trialsthat do not optimiseacute treat-
ment will fail to generalise to clinical situations in
which acute treatment is optimised, in the manner
recommended in current clinical guidelines.
43 Addi-
tional information is thus needed about the benefits
clinicians can expect from the addition of preventive
drugs to contemporary acute treatment.
Trials of acute treatment may provide only a rough
estimate of the benefits of contemporary acute treat-
ment. Trials typically evaluate a single triptan or
other agent relative to placebo for, at most, a few
migraines.
3839 However, contemporary acute treat-
ment involves tailoring the choice of agent (such as
triptan) and route(s) of administration and, if needed,
adjunctive (for example, anti-emetic or non-steroidal
anti-inflammatory) drugs, with the goal of optimising
theeffectivenessandthetolerabilityofacutetreatment
foreachpatient.
75Limitationsofinsurancecoverageor
other financial considerations may well constrain clin-
icians’ ability to optimise acute treatment.
76 However,
this type of tailoring of the acute treatment regimen
remains the clinical goal.
435077 Additional information
abouttheeffectivenessofoptimisedacutetreatment,as
currentlyrecommended,wouldthusbehelpfulineval-
uating treatment options in frequent migraine.
Limitations of study
Our findings are necessarily limited to the preventive
treatment that we evaluated. However, little evidence
indicates that other preventive drugs, including anti-
depressants and anticonvulsants, are more effective
than β blockers for episodic migraine,
3078-90 although
adequately powered comparisons of different preven-
tivedrugsareunavailable.Similarly,wehavelittlerea-
son to believe that other behavioural interventions are
more effective than the behavioural migrainemanage-
ment intervention evaluated here,
323491 although ade-
quatelypoweredcomparisonsofdifferentbehavioural
interventionsalsoareunavailable.Thus,thesefindings
may be generalisable to other preventive drugs and to
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ately designed clinical trials are needed to determine
if this is the case.
Strengthsofthistrialincludearelativelylowattrition
compared with some recent trials,
28-30 a longer evalua-
tion period, electronic daily diary monitoring of head-
aches and drug use for the full 16 months of the trial,
monitoring of adherence, and relatively high adher-
ence to treatments.
3 However, we excluded people
with a diagnosis of medication overuse headaches or
with a comorbid pain disorder as their primary pre-
senting problem in order to evaluate the effect of
migraine specific treatments on both migraines and
migraine related deficits in quality of life. Our results
thus cannot be readily generalised to participants with
these disorders as the primary presenting problem.
Future studies in primary care settings might examine
treatment outcome as a function of comorbid disor-
ders. Also, we cannot exclude the possibility that the
inclusionofadditionaltriptansthathavebecomeavail-
ablesincethistrialwasplannedwouldfurtherincrease
the effectiveness of the optimised acute treatment pro-
tocol,althoughweknowofnoevidencetoindicatethat
this would be the case.
Conclusions
Only thecombinationofβblockertreatmentandbrief
behavioural migraine management improved out-
comes obtained with optimised acute treatment in
this trial. Preventive drugs combined with brief beha-
vioural migraine management may be a promising
method for improving treatment outcomes and, possi-
bly, for reducing progression of migraine and neuro-
degenerative changes seen in the brain in people with
frequent migraine.
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